Search results for " press"

showing 10 items of 4213 documents

The effects of 12-week progressive strength training on strength, functional capacity, metabolic biomarkers, and serum hormone concentrations in heal…

2018

Previous findings suggest that performing strength training (ST) in the evening may provide greater benefit for young individuals. However, this may not be optimal for the older population. The purpose of this study was to compare the effects of a 12-week ST program performed in the morning vs. evening on strength, functional capacity, metabolic biomarker and basal hormone concentrations in older women. Thirty-one healthy older women (66 ± 4 years, 162 ± 4 cm, 75 ± 13 kg) completed the study. Participants trained in the morning (M) (07:30, n = 10), in the evening (E) (18:00, n = 10), or acted as a non-training control group (C) (n = 11). Both intervention groups performed whole-body strengt…

Blood Glucosemaximum strengthmedicine.medical_specialtyEveningWeight LiftingPhysiologyStrength trainingRestBlood lipidsMuscle hypertrophysenior fitness testsresistance03 medical and health sciencesFollicle-stimulating hormone0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumanstime of the dayTestosteroneMuscle StrengthLeg pressMuscle Skeletalta315vuorokaudenajatMorningAgedblood lipidsbusiness.industryagingResistance Training030229 sport sciencesCircadian RhythmharjoitusvasteEndocrinologyikääntyminenFemalevoimaharjoitteluLuteinizing hormonebusiness030217 neurology & neurosurgeryBiomarkersikääntyneetChronobiology International
researchProduct

Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics.

2001

Background. The aim of the present study was to assess the antialbuminuric effect of losartan in a large number of hypertensive type 2 diabetics. Methods. This was a 6-month, open-label, prospective and multicentre study. A total of 422 patients with type 2 diabetes who were hypertensive [sitting systolic blood pressure (SBP) > 140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg] and microalbuminuric [urinary albumin excretion (UAE) 30-300 mg/day] were eligible for the study. After a 2-week run-in period, patients were placed on losartan 50 mg once a day. If the BP did not reach the desired goal (<140/90 mmHg) after a 4-week period, the losartan dose was doubled. In the absence of contr…

Blood Glucosemedicine.medical_specialtySystoleUrologyRenal functionBlood PressureType 2 diabetesLosartanDiabetic nephropathyDiastoleDiabetes mellitusInternal medicinemedicineAlbuminuriaHumansAntihypertensive AgentsGlycated HemoglobinTransplantationbusiness.industryBody Weightmedicine.diseaseAngiotensin IIUric AcidLosartanEndocrinologyBlood pressureHydrochlorothiazideDiabetes Mellitus Type 2NephrologyHypertensionRegression AnalysisMicroalbuminuriaDrug Therapy CombinationbusinessDiabetic Angiopathiesmedicine.drugNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

Effects of oral contraceptives on metabolic profile in women with polycystic ovary syndrome: A meta-analysis comparing products containing cyproteron…

2017

Abstract Background Although oral contraceptives (OCs) are the most common treatment in women with polycystic ovary syndrome (PCOS), their effects and safety on the metabolic profiles of these patients are relatively unknown. In this meta-analysis the effects of the different durations (from 3 months to 1 year) of OC treatment using cyproterone acetate (CA) or third generation progestins on metabolic profile of patients with PCOS were assessed. Materials and methods PubMed, Scopus, Google Scholar and ScienceDirect databases (2001–2015) were searched to identify clinical trials investigating the effects of OC containing CA or third generation progestins on metabolic profiles of women with PC…

Blood Glucosemedicine.medical_specialtyTime Factorsmedicine.drug_classEndocrinology Diabetes and MetabolismBlood lipidsBlood Pressure030209 endocrinology & metabolism03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInsulin resistanceDesogestrelInternal medicinemedicineHumansInsulinCyproterone AcetateClinical Trials as Topic030219 obstetrics & reproductive medicinebusiness.industryBody WeightCyproterone acetateDrospirenoneLipid Metabolismmedicine.diseasePolycystic ovaryEndocrinologychemistryMetabolomeFemaleProgestinsbusinessProgestinBody mass indexContraceptives OralPolycystic Ovary Syndromemedicine.drugMetabolism
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] &gt;300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension

2017

Multicellular interactions of platelets, leukocytes, and the blood vessel wall support coagulation and precipitate arterial and venous thrombosis. High levels of angiotensin II cause arterial hypertension by a complex vascular inflammatory pathway that requires leukocyte recruitment and reactive oxygen species production and is followed by vascular dysfunction. We delineate a previously undescribed, proinflammatory coagulation-vascular circuit that is a major regulator of vascular tone, blood pressure, and endothelial function. In mice with angiotensin II-induced hypertension, tissue factor was up-regulated, as was thrombin-dependent endothelial cell vascular cellular adhesion molecule 1 ex…

Blood PlateletsMale0301 basic medicinemedicine.medical_specialtyMacrophage-1 AntigenVascular Cell Adhesion Molecule-1Blood Pressure030204 cardiovascular system & hematologyThromboplastinMice03 medical and health sciencesTissue factor0302 clinical medicineThrombinInternal medicinemedicineAnimalsHumansPlateletRats WistarEndothelial dysfunctionBlood CoagulationFactor XIAgedMice Knockoutbusiness.industryAngiotensin IIThrombinGeneral MedicineMiddle AgedOligonucleotides Antisensemedicine.diseaseAngiotensin IIMice Inbred C57BL030104 developmental biologyEndocrinologyBlood pressuremedicine.anatomical_structurePlatelet Glycoprotein GPIb-IX ComplexPathophysiology of hypertensionHypertensionFemalebusinessmedicine.drugBlood vesselScience Translational Medicine
researchProduct

Cyclooxygenase-1/2 (COX-1/COX-2) and 5-lipoxygenase (5-LOX) inhibitors of the 6,7-diaryl-2,3-1H-dihydropyrrolizine type

2003

A series of 6,7-diaryl-2,3-1H-dihydropyrrolizines was prepared as COX-1/COX-2 and 5-LOX inhibitors. The inhibition of COX-1 was evaluated using intact bovine platelets as the enzyme source, whereas LPS-stimulated human monocytes served as the enzyme source for inducible COX-2. The determination of arachidonic metabolites was performed by HPLC for COX-1 and RIA for COX-2. The balance between COX-1/COX-2 and 5-LOX inhibition can be shifted by modifying the substitution pattern of the phenyl moiety at the 6- and 7-position of the pyrrolizine nucleus. Structure-activity relationships are discussed.

Blood PlateletsRadioimmunoassayHigh-performance liquid chromatographyIsozymeMonocytesDrug DiscoverymedicineCox 1 cox 2AnimalsHumansMoietyStructure–activity relationshipPyrrolesPlateletLipoxygenase InhibitorsEnzyme InhibitorsChromatography High Pressure LiquidPharmacologychemistry.chemical_classificationbiologyChemistryOrganic ChemistryMembrane ProteinsGeneral MedicineIn vitroIsoenzymesmedicine.anatomical_structureEnzymeBiochemistryCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme inhibitorDrug DesignArachidonate 5-lipoxygenaseCyclooxygenase 1biology.proteinCattleCyclooxygenaseNucleusEuropean Journal of Medicinal Chemistry
researchProduct

PRESSIONI INTRACRANICHE

2008

Blood flow pressures cerebral.Flusso sanguigno cerebrale pressione sistolica pressione di perfusione.Settore VET/01 - Anatomia Degli Animali DomesticiSettore VET/02 - Fisiologia Veterinaria
researchProduct

Blood pressure control in treated hypertensive patients in daily practice of Latvian family physicians.

2011

Background and Objective. The aim of this study was to evaluate blood pressure (BP) control level in treated hypertensive patients in Latvia and to compare their characteristics according to the adequacy of BP control. Materials and Methods. Family physicians collected information on demographic and clinical characteristics, and current antihypertensive treatment of 455 18–80-year-old patients with essential arterial hypertension treated for 1 or more years. Target BP was defined as values of &lt;140/90 mm Hg for patients with low or moderate cardiovascular risk and &lt;135/85–125/75 mm Hg for patients with high or very high risk. BP was measured in the office setting after a 5-minute rest …

Blood pressure controlAdultMalemedicine.medical_specialtyAdolescentBlood Pressurearterial hypertension; blood pressure control; antihypertensive drugsSittingYoung AdultRisk groupsInternal medicineDaily practicemedicineAneroid sphygmomanometerHumansIn patientAntihypertensive AgentsAgedAged 80 and overControl levelbusiness.industryPhysicians FamilyBlood Pressure DeterminationGeneral MedicineMiddle AgedLatviaBlood pressureTreatment OutcomeHypertensionPhysical therapyFemalebusinessMedicina (Kaunas, Lithuania)
researchProduct

Home blood pressure control is low during the critical morning hours in patients with hypertension: the SURGE observational study

2011

Background. The morning blood pressure (BP) surge is associated with a peak increase in vascular events. Objective. The aim of this observational study was to evaluate morning BP control in treated hypertensive patients using home BP (HBP) monitoring and to compare these findings with clinic BP control. Methods. Clinic BP was measured twice during a 2-week period, prior to medication. Seated HBP was measured, using a BHS-validated device, three times per day over a 2-week period. Assessments included morning (06:00–11:59), lunchtime (12:00–14:00) and evening (18:00–22:00) HBP control (all <135/85 mmHg) and clinic BP (<140/90 mmHg) control. Results. A total of 15 618 patients were assessed. …

Blood pressure controlAdultMalemedicine.medical_specialtyEveningTime FactorsAdolescentPopulationYoung AdultMedicineHumansIn patientHome blood pressure monitoring hypertension morning blood pressure control.educationAntihypertensive AgentsMorningAgedAged 80 and overeducation.field_of_studybusiness.industryBlood Pressure DeterminationMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedSurgeryCircadian RhythmBlood pressureTreatment OutcomeAnesthesiaHypertensionObservational studyFemaleDrug MonitoringFamily Practicebusiness
researchProduct

Effectiveness of an Interventional Program to Improve Blood Pressure Control in Hypertensive Patients at High Risk for Developing Heart Failure: HERO…

2010

J Clin Hypertens (Greenwich). The Efectividad de un Programa de Intervencion en el Control de la Presion Arterial de los Hipertensos en Riesgo de Desarrollar Insuficiencia Cardiaca (HEROIC) study was designed to assess whether an educational program for primary care physicians could improve blood pressure (BP) control in hypertensive patients at high risk for developing heart failure. The program contained a combination of educational training (live group sessions or online training) and information feedback. Two hundred twenty-six physicians completed the program and provided valid data in 2489 patients before and 2168 after 1 year. There was a small but significant reduction of −1.1 mm Hg…

Blood pressure controlMaleRiskmedicine.medical_specialtyEndocrinology Diabetes and MetabolismDeveloping heartBlood PressurePrimary carePhysiciansInternal MedicineMedicineHumansProspective StudiesPractice Patterns Physicians'Intensive care medicineAntihypertensive AgentsAgedHeart FailurePrimary Health Carebusiness.industrymedicine.diseaseOriginal PapersBlood pressureCross-Sectional StudiesTreatment OutcomeSpainHeart failureEmergency medicineHypertensionPractice Guidelines as TopicEducation Medical ContinuingFemaleCardiology and Cardiovascular MedicinebusinessInformation feedbackEducational programEducational trainingJournal of clinical hypertension (Greenwich, Conn.)
researchProduct